Reduction of prostate cancer incidence by naftopidil, an α1‐adrenoceptor antagonist and transforming growth factor‐β signaling inhibitor

No abstract is available for this paper.

• Publication year

  2013

• Venue

  International journal of urology

• Publication date

  2013-12-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/iju.12156PMID 23600973
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Transforming growth factor (TGF)-β expression and activation mechanisms as potential targets for anti-tumor therapy and tumor imaging.

  2012cited by this paper
• Detailed analysis of expression and promoter methylation status of apoptosis-related genes in prostate cancer

  2010cited by this paper
• The Prostate 69 : 610 ^ 623 ( 2009 ) Piperazine-Designed a 1 A / a 1 D-AdrenoceptorBlocker KMUP-1 andDoxazosin ProvideDown-Regulationof AndrogenReceptor andPSAin Prostatic LNCaPCells Growthand Specifically inXenografts

  2009cited by this paper
• The TGF-beta paradox in human cancer: an update.

  2009cited by this paper
• Naftopidil, a selective α‐1 adrenoceptor antagonist, inhibits growth of human prostate cancer cells by G1 cell cycle arrest

  2008cited by this paper
• Synthesis and evaluation of [2-(4-quinolyloxy)phenyl]methanone derivatives: novel selective inhibitors of transforming growth factor-beta kinase.

  2008cited by this paper
• Transforming Growth Factor-β and the Immune Response: Implications for Anticancer Therapy

  2007cited by this paper
• Effect of alpha1-adrenoceptor antagonist exposure on prostate cancer incidence: an observational cohort study.

  2007cited by this paper
• Effect of α1-Adrenoceptor Antagonist Exposure on Prostate Cancer Incidence: An Observational Cohort Study

  2007cited by this paper
• Prazosin displays anticancer activity against human prostate cancers: targeting DNA and cell cycle.

  2007cited by this paper
• Doxazosin induces apoptosis of benign and malignant prostate cells via a death receptor-mediated pathway.

  2006cited by this paper
• Transforming growth factor-beta promotes invasion in tumorigenic but not in nontumorigenic human prostatic epithelial cells.

  2006cited by this paper
• Immunohistochemical expression of Bcl2 is an independent predictor of time-to-biochemical failure in patients with clinically localized prostate cancer following radical prostatectomy.

  2005cited by this paper
• Development of TGF-beta signalling inhibitors for cancer therapy.

  2004cited by this paper
• Development of TGF-β signalling inhibitors for cancer therapy

  2004cited by this paper
• Quinazoline-based α1-adrenoceptor antagonists induce prostate cancer cell apoptosis via TGF-β signalling and IκBα induction

  2003cited by this paper
• Maspin sensitizes prostate cancer cells to doxazosin-induced apoptosis

  2003cited by this paper
• Immunoexpressions of p21, Rb, mcl-1 and bad gene products in normal, hyperplastic and carcinomatous human prostates.

  2002cited by this paper
• Quinazoline-derived α1-Adrenoceptor Antagonists Induce Prostate Cancer Cell Apoptosis Via an α1-Adrenoceptor-independent Action

  2002cited by this paper
• Quinazoline-derived alpha1-adrenoceptor antagonists induce prostate cancer cell apoptosis via an alpha1-adrenoceptor-independent action.

  2002cited by this paper
• Suppression of human prostate cancer cell growth by alpha1-adrenoceptor antagonists doxazosin and terazosin via induction of apoptosis.

  2000cited by this paper
• Adrenergic and cholinergic regulation of apoptosis and differentiation of thymic lymphocytes.

  1994cited by this paper
• Pharmacokinetics of naftopidil, a novel anti-hypertensive drug, in patients with hepatic dysfunction.

  1994cited by this paper
• Apoptosis: A Basic Biological Phenomenon with Wide-ranging Implications in Tissue Kinetics

  1972cited by this paper
• Shrinkage necrosis: A distinct mode of cellular death

  1971cited by this paper

• Effects of chronic stress on cancer development and the therapeutic prospects of adrenergic signaling regulation.

  2024cites this paper
• Repurposed Drugs in Gastric Cancer

  2022cites this paper
• Classification of Clear Cell Renal Cell Carcinoma based on Tumor Suppressor Genomic Profiling

  2021cites this paper
• Human Prostate Tissue MicroRNAs and Their Predicted Target Pathways Linked to Prostate Cancer Risk Factors

  2021cites this paper
• Bim, Puma and Noxa upregulation by Naftopidil sensitizes ovarian cancer to the BH3-mimetic ABT-737 and the MEK inhibitor Trametinib

  2020cites this paper
• A Pilot retrospective analysis of alpha-blockers on recurrence in men with localised prostate cancer treated with radiotherapy

  2020cites this paper
• Impact of Concomitant Medications on Biochemical Outcome in Localised Prostate Cancer Treated with Radiotherapy and Androgen Deprivation Therapy.

  2020cites this paper
• Drug Repositioning of the α1-Adrenergic Receptor Antagonist Naftopidil: A Potential New Anti-Cancer Drug?

  2020influential citation
• TGF-β causes Docetaxel resistance in Prostate Cancer via the induction of Bcl-2 by acetylated KLF5 and Protein Stabilization

  2020cites this paper
• Effects of α1-adrenergic receptor antagonists on the development and progression of urothelial cancer.

  2020cites this paper
• Alpha-1 blocker use increased risk of subsequent renal cell carcinoma: A nationwide population-based study in Taiwan

  2020cites this paper
• Impact of α-adrenoceptor antagonists on prostate cancer development, progression and prevention.

  2019cites this paper
• Naftopidil reduced the proliferation of lung fibroblasts and bleomycin‐induced lung fibrosis in mice

  2019cites this paper
• Identification of HUHS190, a human naftopidil metabolite, as a novel anti-bladder cancer drug.

  2019cites this paper
• A prospective randomized controlled study on the Suppression of Prostate Cancer by Naftopidil (SNAP)

  2018influential citation
• Autophagy Induced by Naftopidil Inhibits Apoptosis of Human Gastric Cancer Cells.

  2018cites this paper
• Human UDP-Glucuronosyltransferase 2B4 and 2B7 Are Responsible for Naftopidil Glucuronidation in Vitro

  2018cites this paper
• Partial agonist activity of α1-adrenergic receptor antagonists for chemokine (C-X-C motif) receptor 4 and atypical chemokine receptor 3

  2018cites this paper
• Effects of High Concentrations of Naftopidil on Dorsal Root-Evoked Excitatory Synaptic Transmissions in Substantia Gelatinosa Neurons In Vitro

  2018cites this paper
• Drug Repurposing in Anticancer Reagent Development.

  2017cites this paper
• Sympathetic nervous system promotes hepatocarcinogenesis by modulating inflammation through activation of alpha1-adrenergic receptors of Kupffer cells.

  2017cites this paper
• Additive naftopidil treatment synergizes docetaxel-induced apoptosis in human prostate cancer cells

  2017cites this paper
• Piperazine-based Alpha-1 AR Blocker, Naftopidil, Selectively Suppresses Malignant Human Bladder Cells via Induction of Apoptosis.

  2016cites this paper
• A selective alpha1D-adrenoreceptor antagonist inhibits human prostate cancer cell proliferation and motility "in vitro".

  2016cites this paper
• Possible new therapeutic agents for malignant pleural mesothelioma: anti-CD26 monoclonal antibody and naftopidil

  2016cites this paper
• The role of alpha 1-adrenoceptor antagonists in the treatment of prostate and other cancers

  2016cites this paper
• Adrenoceptor modulators and cancer progression

  2016cites this paper
• Pharmaceutical evaluation of naftopidil enantiomers: Rat functional assays in vitro and estrogen/androgen induced rat benign prostatic hyperplasia model in vivo.

  2016cites this paper
• Novel naftopidil-related derivatives and their biological effects as alpha1-adrenoceptors antagonists and antiproliferative agents.

  2015cites this paper
• Enantiospecific determination of naftopidil by RRLC-MS/MS reveals stereoselective pharmacokinetics and tissue distributions in rats.

  2015cites this paper
• Repositioned alpha-1 adrenoceptor blockers as anti-tumor drugs

  2015cites this paper
• Editorial Comment from Dr Chen to Reduction of prostate cancer incidence by naftopidil, an α1‐adrenoceptor antagonist and transforming growth factor‐β signaling inhibitor

  2013cites this paper
• Editorial Comment from Dr Murtola to Reduction of prostate cancer incidence by naftopidil, an α1‐adrenoceptor antagonist and transforming growth factor‐β signaling inhibitor

  2013cites this paper
• International Journal of Molecular Sciences the Role of Α1-adrenoceptor Antagonists in the Treatment of Prostate and Other Cancers

  year unknowncites this paper